Cytochroma
Accelerating global drug development
Accelerating global drug development
Cytochroma is a biotechnology startup based in the United Kingdom founded in 2017 with the slogan "Accelerating global drug development". The company specializes in predicting how drugs will react in a global population in health or disease. Cytochroma boasts a unique, ethnically diverse library of iPSC and automated cell culture that generates robust, reliable, mature hepatocytes for toxicity testing. The company's services aim to support life science companies, de-risk safe compounds prior to clinical testing, and make new drug development faster, safer, and more efficient.
Notably, Cytochroma recently secured a £1.00M Seed Round investment on 16 December 2021 from Cambridge Capital Group, Angel Academe, Investing Women. This strategic investment is a testament to the potential and promise of Cytochroma's innovative approach to drug development, highlighting investor confidence in the company's vision and capabilities.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | £1.00M | 3 |
|
16 Dec 2021 |
| Grant | Unknown | 2 |
|
16 Dec 2021 |
No recent news or press coverage available for Cytochroma.
We care about your data, and we'd love to use cookies make your experience better.